Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
2.350
-0.010 (-0.42%)
Nov 4, 2024, 3:51 PM EST - Market closed
Armata Pharmaceuticals Employees
Armata Pharmaceuticals had 66 employees as of December 31, 2023. The number of employees decreased by 9 or -12.00% compared to the previous year.
Employees
66
Change (1Y)
-9
Growth (1Y)
-12.00%
Revenue / Employee
$56,348
Profits / Employee
-$1,015,803
Market Cap
85.03M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Agenus | 389 |
Coherus BioSciences | 306 |
PetMed Express | 287 |
I-Mab | 220 |
X4 Pharmaceuticals | 93 |
PMV Pharmaceuticals | 63 |
Ikena Oncology | 43 |
Vistagen Therapeutics | 40 |
ARMP News
- 5 days ago - Armata Pharmaceuticals Announces Structural Biology Publication - PRNewsWire
- 2 months ago - Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - PRNewsWire
- 2 months ago - Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium - PRNewsWire
- 2 months ago - Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - PRNewsWire
- 2 months ago - Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 - PRNewsWire